>Year 2005, Issue 4
Delgadillo TGH, González RF, Fenig RJ, Velázquez GA, Galindo ML, Bevia PF
Experience in the surgical management of pheochromocytoma
Cir Gen 2005; 27 (4)
PDF: 4. Kb.
Objective:To know the frequency of presentation of pheochromocytoma at the Specialty Hospital of the Centro Medico Nacional “La Raza”, IMSS, in Mexico City.
Setting:Third level health care institution.
Design:Retrospective, descriptive, transversal study.
Patients and methods:We analyzed the clinical and histological records of all patients with a diagnosis of pheochromocytoma, with a suprarenal location, from January 1989 to December 2000.
Results:A total of 31 patients with pheochromocytoma, suprarenal location, were attended; 87% were women and 13% were men. Average age of presentation was 31 years: The clinical symptoms were characterized by headache, hard to control arterial hypertension, and diaphoresis in 97% of the cases. Diagnosis was reached by determining the presence of catecholamines in a 24-hours urine sample and through an abdominal CAT scan. Affection of the right suprarenal gland was more frequent with 88% of the cases, the left with 9%, and in 3% the affection was bilateral. The most frequent complication was postoperative bleeding in 19% and pancreatitis in one patient. Mortality was of 3%. Histologically, the pathology was benign in 97% and malignant in 3%.
Conclusions:Affection of the suprarenal gland by a pheochromocytoma is a rare pathology in our milieu, it affects more frequently women; a hard to control hypertension is the most frequent sign in young patients, presenting as headache.
||Pheochromocytoma, hypertension, suprarenal gland.
Scully RE, Mark EJ, McNeely WF, Ebeling SH. Case records of the Massachusetts General Hospital. Case 27-1996. N Engl J Med 1996; 335: 650-5.
Lairmore TC, Ball DW, Baylin SB. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993; 217: 595-603.
Neumann HP, Berger DP, Sigmund G. Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-38.
Landsberg L, Young JB. Pheochromocytoma. In: Braunwald E, Issebalcher HJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, editors. Harrison’s Principles of Internal Medicine. 13th Ed. New York. Mc Graw Hill. 1995.
Sclafani LM, Woodruff JM, Brennan MF. Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment. Surgery 1990; 108: 1124-29.
Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1-10.
Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one Institution’s experience. Medicine 1991; 70: 46-66.
Lenders JW, Keiser HR, Goldstein DS. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123: 101-9.
Elijovich F. Plasma metanephrines in the diagnosis of pheochromocytoma. Letter to the Editor. Ann Intern Med 1996; 124: 694-5.
Freier D, Mccleod M. Pheochromocytoma new paradigms for an old tumor. Cir Gen 2000; 22: 232-5.
Bravo EL, Gifford RW. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298-1303.
Shapiro B, Copp JE, Sisson JC. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nuclear Med 1985; 26: 576-85.
Brennan MF, Keiser HR. Persistent and recurrent pheochromocytoma: the role of surgery. World J Surg 1982; 6: 397-402.
>Year 2005, Issue 4